News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,762 Results
Type
Article (14572)
Company Profile (284)
Press Release (259895)
Multimedia
Podcasts (65)
Webinars (12)
Section
Business (79688)
Career Advice (154)
Deals (13274)
Drug Delivery (38)
Drug Development (50579)
Employer Resources (31)
FDA (5782)
Job Trends (5154)
News (144754)
Policy (10059)
Tag
Academia (917)
Accelerated approval (8)
Adcomms (14)
Allergies (64)
Alliances (21761)
ALS (91)
Alzheimer's disease (941)
Antibody-drug conjugate (ADC) (142)
Approvals (5845)
Artificial intelligence (177)
Autoimmune disease (33)
Automation (7)
Bankruptcy (105)
Best Places to Work (4558)
BIOSECURE Act (6)
Biosimilars (65)
Biotechnology (231)
Bladder cancer (79)
Brain cancer (31)
Breast cancer (230)
Cancer (2152)
Cardiovascular disease (169)
Career advice (136)
Career pathing (2)
CAR-T (158)
CDC (4)
Cell therapy (424)
Cervical cancer (11)
Clinical research (42182)
Collaboration (792)
Company closure (2)
Compensation (423)
Complete response letters (27)
COVID-19 (1070)
CRISPR (71)
C-suite (314)
Cystic fibrosis (92)
Data (2578)
Denatured (13)
Depression (60)
Diabetes (197)
Diagnostics (1327)
Digital health (4)
Diversity (4)
Diversity, equity & inclusion (9)
Drug discovery (120)
Drug pricing (36)
Drug shortages (3)
Duchenne muscular dystrophy (162)
Earnings (30929)
Editorial (21)
Employer branding (4)
Employer resources (29)
Events (50019)
Executive appointments (568)
FDA (6974)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (696)
Gene editing (138)
Generative AI (12)
Gene therapy (361)
GLP-1 (440)
Government (1118)
Grass and pollen (2)
Guidances (143)
Healthcare (6604)
HIV (12)
Huntington's disease (31)
IgA nephropathy (44)
Immunology and inflammation (137)
Immuno-oncology (8)
Indications (29)
Infectious disease (1147)
Inflammatory bowel disease (134)
Inflation Reduction Act (9)
Influenza (26)
Intellectual property (115)
Interviews (18)
IPO (7321)
IRA (12)
Job creations (866)
Job search strategy (127)
Kidney cancer (8)
Labor market (15)
Layoffs (231)
Leadership (5)
Legal (1394)
Liver cancer (38)
Longevity (8)
Lung cancer (313)
Lymphoma (158)
Machine learning (13)
Management (7)
Manufacturing (241)
MASH (88)
Medical device (2624)
Medtech (2628)
Mergers & acquisitions (6414)
Metabolic disorders (539)
Multiple sclerosis (76)
NASH (13)
Neurodegenerative disease (118)
Neuropsychiatric disorders (35)
Neuroscience (1567)
NextGen: Class of 2025 (2021)
Non-profit (858)
Now hiring (26)
Obesity (250)
Opinion (110)
Ovarian cancer (91)
Pain (70)
Pancreatic cancer (97)
Parkinson's disease (162)
Partnered (9)
Patents (218)
Patient recruitment (178)
Peanut (40)
People (26124)
Pharmaceutical (46)
Pharmacy benefit managers (5)
Phase I (14898)
Phase II (19620)
Phase III (12385)
Pipeline (1571)
Policy (76)
Postmarket research (853)
Preclinical (6325)
Press Release (30)
Prostate cancer (97)
Psychedelics (44)
Radiopharmaceuticals (221)
Rare diseases (412)
Real estate (1430)
Recruiting (12)
Regulatory (9145)
Reports (19)
Research institute (946)
Resumes & cover letters (17)
Rett syndrome (10)
RNA editing (15)
RSV (12)
Schizophrenia (94)
Series A (129)
Series B (94)
Service/supplier (1)
Sickle cell disease (56)
Special edition (16)
Spinal muscular atrophy (118)
Sponsored (13)
Startups (1992)
State (1)
Stomach cancer (5)
Supply chain (27)
Tariffs (16)
The Weekly (51)
Vaccines (283)
Venture capital (44)
Weight loss (136)
Women's health (18)
Worklife (2)
Date
Today (77)
Last 7 days (267)
Last 30 days (1321)
Last 365 days (18471)
2025 (12943)
2024 (20549)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (151)
Alabama (57)
Alaska (2)
Arizona (59)
Arkansas (5)
Asia (17760)
Australia (3007)
California (5417)
Canada (1487)
China (552)
Colorado (198)
Connecticut (206)
Delaware (159)
Europe (38152)
Florida (680)
Georgia (171)
Hawaii (2)
Idaho (16)
Illinois (310)
India (19)
Indiana (121)
Iowa (7)
Japan (137)
Kansas (72)
Kentucky (6)
Louisiana (4)
Maine (11)
Maryland (598)
Massachusetts (4312)
Michigan (90)
Minnesota (201)
Mississippi (3)
Missouri (26)
Montana (14)
Nebraska (4)
Nevada (25)
New Hampshire (15)
New Jersey (1311)
New Mexico (12)
New York (1400)
North Carolina (697)
North Dakota (6)
Northern California (2493)
Ohio (143)
Oklahoma (10)
Oregon (21)
Pennsylvania (1002)
Puerto Rico (7)
Rhode Island (24)
South America (210)
South Carolina (6)
Southern California (2109)
Tennessee (31)
Texas (686)
United States (18224)
Utah (76)
Virginia (114)
Washington D.C. (36)
Washington State (455)
West Virginia (1)
Wisconsin (28)
274,762 Results for "skyhawk therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neuroscience
Merck KGaA Drops up to $2B in Skyhawk Collab for RNA-Targeting Tech
Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since launching in 2018.
August 18, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
September 18, 2025
·
4 min read
Press Releases
Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders
August 19, 2025
·
3 min read
Press Releases
Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington’s Disease
June 17, 2025
·
4 min read
Press Releases
Skyhawk Therapeutics Presents at Huntington’s Disease Youth Organization HDYO International Congress 2025
March 17, 2025
·
2 min read
Business
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman
Skyhawk Therapeutics, Inc. announced the promotion of Clint Musil, former Chief Financial Officer of Skyhawk Therapeutics, to Chief Executive Officer and the appointment of Bill Haney, former Chief Executive Officer and Co-founder of Skyhawk Therapeutics, to Executive Chairman of the Board of Directors.
June 11, 2024
·
5 min read
Genetown
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases.
April 22, 2024
·
7 min read
Business
Ipsen, Skyhawk Ink Potential $1.8B Deal to Target RNA in Neuro Diseases
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
April 22, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Skyhawk Therapeutics to Present Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
October 17, 2024
·
2 min read
Press Releases
Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington’s Disease Patient Trial
December 10, 2024
·
3 min read
1 of 27,477
Next
